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We examined the antigenic structure of human hepatitis A virus (HAV) by characterizing a series of 21
murine monoclonal-antibody-resistant neutralization escape mutants derived from the HM175 virus strain.
The escape phenotype of each mutant was associated with reduced antibody binding in radioimmunofocus
assays. Neutralization escape mutations were identified at the Asp-70 and Gln-74 residues of the capsid protein
VP3, as well as at Ser-102, Val-171, Ala-176, and Lys-221 of VP1. With the exception of the Lys-221 mutants,
substantial cross-resistance was evident among escape mutants tested against a panel of 22 neutralizing
monoclonal antibodies, suggesting that the involved residues contribute to epitopes composing a single antigenic
site. As mutations at one or more of these residues conferred resistance to 20 of 22 murine antibodies, this site
appears to be immunodominant in the mouse. However, multiple mutants selected independently against any
one monoclonal antibody had mutations at only one or, at the most, two amino acid residues within the capsid
proteins, confirming that there are multiple epitopes within this antigenic site and suggesting that single-amino-
acid residues contributing to these epitopes may play key roles in the binding of individual antibodies. A
second, potentially independent antigenic site was identified by three escape mutants with different substitu-
tions at Lys-221 of VP1. These mutants were resistant only to antibody H7C27, while H7C27 effectively
neutralized all other escape mutants. These data support the existence of an immunodominant neutralization
site in the antigenic structure of hepatitis A virus which involves residues of VP3 and VP1 and a second,
potentially independent site involving residue 221 of VP1.
X-ray crystallographic determinations of virus structures
have contributed substantially to current understanding of
the structural organization and function of picornaviruses (1,
15, 26, 32). Combined with the analysis of neutralization
escape mutants selected for resistance to monoclonal anti-
bodies, structural studies have provided a uniquely detailed
view of the antigenic features of these viruses (6, 28, 32).
However, technical difficulties have severely hampered such
studies with human hepatitis A virus (HAV), a medically
important virus now classified as the type species of the
genus Hepatovirus within the family Picornaviridae (14).
The replication cycle of HAV in cell culture is relatively
slow, and yields of virus are considerably lower than those
obtained with most other picornaviruses (4). Thus, produc-
tion of the quantities of purified virus that are required for
crystallographic studies represents a daunting task. In addi-
tion, HAV replication is usually nonlytic and neutralization
ofHAV in vitro is often relatively inefficient (19), making the
isolation and characterization of neutralization escape mu-
tants both tedious and difficult.
Nonetheless, some information concerning the antigenic
structure of HAV has been obtained from studies with a very
limited number of escape mutants. By repetitive cycles of
neutralization and amplification of virus in the presence of
murine monoclonal antibodies, we previously isolated a
small series of escape mutants (31, 34). Neutralization stud-
ies with these escape mutants and a related panel of mono-
clonal antibodies suggested that most murine antibodies
recognize a dominant antigenic site on the virus capsid.
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These results were further supported by studies examining
competition between various monoclonal antibodies for
binding to the surface of the virus capsid (16, 31, 34).
Sequencing studies indicated that the Asp-70 residue of
capsid protein VP3 (Asp 3-070) (in this paper, we use
four-digit nomenclature to describe specific amino acid res-
idues; i.e., "y-nnn," in which "y" represents the capsid
protein [VP1, VP2, or VP3] and "nnn" represents the
residue number from the proposed amino terminus [9]) plays
a critical role in forming this antigenic site, while a lesser
contribution is made by Ser 1-102 (31). These residues are
well conserved among human HAV strains, consistent with
the highly conserved antigenic characteristics of this virus.
Subsequent mutagenesis studies with infectious cDNA have
confirmed the importance of Asp 3-070 in the antigenic
structure of HAV (11).
In this report, we describe the isolation and characteriza-
tion of an expanded series of HAV escape mutants that
resist neutralization by one or more murine monoclonal
antibodies. Results of these studies are consistent with a
critical role for Asp 3-070 in the structure of an immuno-
dominant antigenic site, but they also document the contri-
bution of additional residues of VP1 to this domain and
suggest the existence of a second, potentially independent
antigenic site involving other residues of VP1. These results
are of interest because they shed additional light on the
structure of this virus and thus allow further comparisons of
HAV with other picornaviruses. A better understanding of
the antigenic structure ofHAV is also relevant to the rational
design of new vaccines, which are needed for improved
control of type A viral hepatitis in many human populations
(33).
2208
Vol. 66, No. 4
HAV NEUTRALIZATION ESCAPE MUTANTS 2209
MATERIALS AND METHODS
Virus and cells. Virus was propagated in continuous Afri-
can green monkey kidney (BS-C-1) cells, which were grown
as monolayers in Eagle's minimal essential medium with
Earle's salts (EMEM) supplemented with 100 mM glu-
tamine, streptomycin (100 pg/ml), penicillin (100 U/ml), and
2 to 10% fetal bovine serum (4). Neutralization escape
mutants were selected from a clonally isolated, rapidly
replicating, cytopathic (RR/CPE+) variant of the HM175
strain of HAV, HM175/18f virus (25), as described in detail
below. HM175/18f is highly adapted to growth in cell culture
and contains two capsid protein mutations, while its parent,
HM175/p16, is an RR/CPE- virus which has undergone only
16 passages in cell culture. These mutations, which include
substitutions of Thr 3-091 with Lys and Ser 1-271 with Pro,
do not alter the antigenicity of HM175/18f virus in solid-
phase immunoassays utilizing a panel of murine monoclonal
antibodies (25). Previously described escape mutants (S30
and S32) were isolated from HM175/p16 virus (34), while
HM175/43c is a spontaneous RR/CPE+ neutralization es-
cape mutant recovered from persistently infected cells in the
absence of any antibody-related selective pressure (25). This
virus lacks the two capsid mutations of HM175/18f but has
three other amino acid substitutions in the capsid proteins as
described previously (25, 31). HM175/30M is another spon-
taneous escape mutant which was initially identified in an
epitope-specific (K24F2) radioimmunofocus assay (see be-
low) of cells infected with HM175/18f virus in the absence of
any selective antibody pressure, and it was clonally isolated
as described below.
Monoclonal antibodies to HAV. Hybridoma cells secreting
antibodies 1.193 and 1.134 were selected from the fusion
products of P3-8.653 cells (American Type Culture Collec-
tion) and spleen cells harvested from BALB/c mice immu-
nized with gradient-purified HM175/18f virus. Antibody-
secreting hybridomas were identified by testing supernatant
fluids of cultures in an indirect radioimmunoassay. In this
assay, 96-well polyvinylchloride microplates were coated
with goat antibody to mouse immunoglobulins (immunoglob-
ulin G [IgG], IgM, and IgA) and then loaded with superna-
tant fluids from hybridoma cultures. Virus-specific antibod-
ies captured to the solid phase were identified by their ability
to bind virus present in crude lysates of infected cells;
immobilized viral antigen was subsequently detected by
incubation with 125"-labelled human polyclonal (JC) antibody
to HAV. Other monoclonal antibodies were provided as gifts
from multiple investigators or were purchased from Com-
monwealth Serum Laboratories, Melbourne, Australia (see
Table 1). Antibody preparations utilized in these studies
included hybridoma culture supernatants, purified immuno-
globulins, and mouse ascitic fluids.
When the immunoglobulin class of a monoclonal antibody
was not known from its original source, antibodies present in
hybridoma culture fluids were typed by using an Immuno-
Select kit purchased from Bethesda Research Laboratories,
Bethesda, Md. Monoclonal antibodies present in ascitic
fluids were typed by using a modification of this procedure.
Antibodies in ascitic fluids were captured onto the wells of
96-well plates with immunoglobulin subclass-specific anti-
bodies (ImmunoSelect; Bethesda Research Laboratories),
and antibodies specific for HAV were identified by the
sequential addition of virus-infected cell lysates and 1251_
labelled human anti-HAV IgG. For use in immunoassays,
monoclonal antibodies were partially purified by precipita-
tion with 50% ammonium sulfate and then dialyzed against
phosphate-buffered saline and subjected to chloramine-T-
mediated labelling with 125I, as described previously (22).
Virus neutralization. Neutralization of HAV was assessed
in radioimmunofocus-reduction assays as described previ-
ously (18). This method is similar to conventional plaque-
reduction neutralization assays for viruses but involves
staining of acetone-fixed cell sheets with 1251I-labelled anti-
HAV, followed by autoradiography, for visualization of
HAV replication foci. Despite the RR/CPE+ phenotype of
HM175/18f virus, the radioimmunofocus assay remains the
most reliable method for determining the infectious titer of
this virus.
Solid-phase radioimmunoassays. Solid-phase radioimmu-
noassays for HAV and anti-HAV antibodies were carried
out as described previously (24). Assays determining the
ability of individual monoclonal antibodies to compete with
polyclonal or other monoclonal antibodies for binding to
HAV have also been described elsewhere (34). In these
assays, fivefold dilution series of each monoclonal antibody
were tested for activity in blocking the binding of 12511
labelled human polyclonal (JC) or similarly labelled mono-
clonal K34C8 and B5B3 antibodies to virus which had been
captured onto a solid-phase support by human polyclonal
antibody. The competing unlabelled antibody was present in
substantial molar excess over the radiolabelled antibody,
such that antibody concentration was not limiting with
respect to blocking activity.
Selection of neutralization escape mutants. Attempts to
neutralize HAV almost always result in substantial nonspe-
cific nonneutralized fractions (19), even after vigorous at-
tempts to eliminate virus aggregation. Thus, we subjected
virus to repeated cycles of neutralization followed by ampli-
fication in the presence of murine monoclonal antibodies,
using a general approach that we have described previously
(34). However, to facilitate the process of mutant selection,
we utilized an epitope-specific radioimmunofocus assay
technique (21, 25) following the first three to four cycles of
neutralization and virus amplification, as shown in Fig. 1. To
reduce aggregation, HM175/18f virus was brought to 0.1%
sodium dodecyl sulfate (SDS) and held at 37°C for 30 min.
This was followed by extraction with an equal volume of
chloroform and sonication for 3 min. An aliquot containing
approximately 107 radioimmunofocus-forming units was
neutralized by incubation with a monoclonal antibody (2D2,
AD2, AE8, or H7C27) overnight at 4°C followed by incuba-
tion for 1 h at 35.5°C prior to adsorption to nearly confluent
monolayers of BS-C-1 cells in replicate 25-cm2 tissue culture
flasks (three or six flasks, labelled A, B, and C, etc.) for 2 h
at 35.5°C. The concentration of each monoclonal antibody
was 10- to 1,000-fold greater than that required to achieve
50% neutralization of virus. The inoculum was removed, and
the cell sheet was washed three times with EMEM contain-
ing 2% fetal bovine serum. The cells were refed with 5 ml of
maintenance medium containing 1/10th the original concen-
tration of monoclonal antibody and incubated at 35.5°C.
After 7 days of incubation, the medium was removed and
used as a source of virus for the second cycle of neutraliza-
tion-amplification (Fig. 1). This medium was extracted once
with an equal volume of chloroform prior to the addition of
fresh antibody for the subsequent neutralization cycle.
After three to four cycles of neutralization-amplification,
the neutralization resistance of virus present in cell culture
supernatant fluids was assessed in an epitope-specific radio-
immunofocus assay (21). This virus was treated with SDS
and neutralized with monoclonal antibody as described
above, and 10-fold dilutions of neutralized virus were inoc-
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FIG. 1. Approach taken for the isolation of neutralization escape
variants of HM175/18f virus. For each monoclonal antibody, three
(AD2, AE8, and H7C27) or six (2D2) replicate cultures of BS-C-1
cells were inoculated with neutralized virus. Virus harvested from
supernatant fluids of each culture was carried through three to four
cycles of neutralization-amplification in BS-C-1 cells with antibody
maintained in the medium, and progeny were examined for resistant
virus clones by an epitope-specific (double-antibody) radioimmuno-
focus assay (2-Ab RIFA) employing the cognate monoclonal anti-
body. At least two neutralization-resistant virus clones were se-
lected from each neutralization-amplification culture series and
amplified in BS-C-1 cells for determination of the neutralization
resistance phenotype and PCR-based sequence analysis. RFU,
radioimmunofocus-forming units.
ulated onto nearly confluent BS-C-1 cell monolayers in
60-mm-diameter polystyrene petri dishes. After 2 h of virus
adsorption, the cell sheets were overlaid with medium con-
taining 0.5% SeaKem agarose. Following 7 days of incuba-
tion at 35.5°C in a 5% CO2 atmosphere, the overlay was
carefully removed and placed at 4°C and the cells were fixed
with 80% acetone and stained with the cognate 125I-labelled
monoclonal antibody (20). Following autoradiographic expo-
sure, the cell sheet was counterstained with 12 I-labelled
polyclonal human convalescent antibody (JC) to HAV and a
second autoradiographic exposure was obtained. This
epitope-specific radioimmunofocus assay procedure allowed
the overall neutralization resistance of the virus harvest to
be assessed by comparison of virus titers before and after
neutralization. However, the double-antibody staining pro-
cedure also identified individual virus clones which no longer
bound the monoclonal antibody of interest (21, 25). At least
two monoclonal antibody-resistant clones were recovered
from each original neutralization-amplification culture series
(A, B, and C, etc.) by sampling agarose overlays in the
regions overlying selected radioimmunofoci. Agarose plugs
removed from the overlay were processed for virus recovery
as described previously (23). When the epitope-specific
radioimmunofocus assay results indicated that the virus
harvest was a mixture of resistant and nonresistant viruses,
the resistant (mutant) clones were plaque purified twice by
this procedure. Otherwise, mutant viruses were plaque
purified only once prior to amplification. Virus recovered
from overlays was neutralized overnight with the cognate
antibody and amplified in 25-cm2 flasks in the presence of the
monoclonal antibody to prepare a virus seed for determina-
tion of neutralization resistance to the complete panel of
antibodies and for sequencing of virion RNA. If no escape
mutants were identified in the epitope-specific radioimmun-
ofocus assay, the virus was subjected to an additional three
neutralization-amplification cycles, as described above (Fig.
1).
Analysis of neutralization resistance phenotypes. Escape
mutant harvests were prepared from supernatant fluids of
25-cm2 cell culture flasks 7 days after inoculation of virus,
and the virus titer was determined by radioimmunofocus
assay. A standard inoculum of each mutant virus (approxi-
mately 400 radioimmunofocus-forming units/ml) prepared in
medium containing 2% fetal bovine serum was mixed with an
equal volume of antibody for neutralization as described
above, and the residual virus titer was determined by radio-
immunofocus assay (18). We defined neutralization resis-
tance as <30% neutralization, partial neutralization resis-
tance as 30 to 60% neutralization, and neutralization
sensitivity as >60% neutralization. For comparison, a pa-
rental HM175/18f virus control was included for each mono-
clonal antibody tested in each neutralization assay.
Nucleotide sequence of escape mutants. The partial nucle-
otide sequence of clonally isolated escape mutants was
determined by dideoxynucleotide sequence analysis of the
products of an antigen capture-polymerase chain reaction
(PCR) method described previously (17). Polyclonal human
antibody (JC) was utilized for capture of virus. Positive (+)-
and negative (-)-strand oligodeoxynucleotide primer pairs
utilized for reverse transcription and PCR amplification of
cDNA included (among others) (i) +560/-1501, (ii) +1561/
-1771, (iii) +2646/-3192, (iv) +1561/-2037, (v) +2392/
-2698, (vi) +1308/-1771, (vii) +1998/-2556, and (viii)
+1308/-2556, where the number indicates the position of
the most 5' base within the positive strand represented by
the oligonucleotide (wild-type HM175 numbering) (9). PCR
amplification products were subjected to agarose gel electro-
phoresis and the specific band was excised and extracted
with phenol-chloroform. Multiple positive-strand and nega-
tive-strand primers were utilized for 35S-dideoxynucleotide
sequencing of the double-stranded cDNA. Primer sequences
are available upon request.
RESULTS
Characterization of murine monoclonal antibodies to HAV.
We assembled a panel of 24 murine monoclonal antibodies
raised against eight different strains of human HAV in nine
different laboratories. A total of 4 of these antibodies were of
the IgM isotype, 1 was IgA, and the remaining 19 were IgG
(Table 1). Fifteen IgG antibodies were of the subclass
IgG2A, while two antibodies were IgG3, one was IgG2B,
and one was IgGl. A total of 15 of 16 antibodies for which
the light-chain type was determined were of the K type.
Serial dilutions of monoclonal antibodies were tested for
their ability to block the binding of polyclonal human con-
valescent antibody to HAV in a solid-phase radioimmuno-
assay (Table 1). Eighteen of these antibodies were capable of
blocking polyclonal antibody binding by .50%. In addition,
we characterized each antibody with respect to its ability to
compete against two individual reference monoclonal anti-
HAV antibodies (K34C8 and B5B3) for binding to HAV in
solid-phase immunoassays (Fig. 2). We previously demon-
strated that these two antibodies do not compete with each
other for binding to the virus capsid and that a combination
of these two antibodies is capable of blocking the binding of
polyclonal human antibody almost completely (31, 34). As
shown in Fig. 2, measurement of K34C8- and B5B3-blocking
J. VIROL.
HAV NEUTRALIZATION ESCAPE MUTANTS 2211
TABLE 1. Murine monoclonal antibodies to HAV
Immuno- Maximum % Neutraliza-
Antibody globulin Virus Source' competition tion'
class strain vspcABT
vsPA6 % Titer
K34C8 IgG2A(K) HM790 g 47 92 >5.0
1.193 IgA(K) HM175 h 74 98 4.3
K24F2 IgG2A HM790 g 59 100 >5.0
HlOC29 IgG3 GBM b 39 91
K32F2 IgG2A HM790 g 100 >5.0
813 IgG3(K) CF53 a 54 97
141C19 IgG2A(K) GBM b 60 99
6A5 IgG2A CR326 e 62 91 6.0
AG3 IgG2A(K) S841 f 69 100 3.9
1009 IgGl(K) CF53 a 51 100
H14C42 IgM(A) GBM b 50 96
1B9 IgG2A CR326 e 40 99 3.5
2D2 IgG2A(K) CR326 e 65 94 5.5
3E1 IgG2A CR326 e 65 86 4.0
B5B3 IgG2A KMW1 i 60 98 5.1
H80C25 IgG2A(K) GBM b 65 85
AD2 IgG2A(K) S841 f 87 95 3.4
7E7 IgG2A(K) GBM c 77 96 3.6
AE8 IgM(K) S841 f 66 92 5.3
H29C26 IgG2A(K) GBM b 71 97
H7C27 IgG2B(K) GBM b 70 94 3.7
4E7 IgM(K) GBM c 73 97
1.134 IgM(K) HM175 h 13 <50 <1.0
LSH-14H IgG2A LSH/S d 36 <50 <1.0
a Sources: a, D. Crevat, Clonatec, Paris, France (12); b, R. Decker, Abbott
Laboratories, North Chicago, Ill. (13); c, B. Flehmig, University of Tubingen,
Tubingen, Germany; d, H. Garelick, London School of Tropical Medicine and
Hygiene, London, United Kingdom; e, J. Hughes, Merck Sharp and Dohme
Research Laboratories, West Point, Pa. (16); f, C. Li, Sichuan Health and
Anti-Epidemic Station, China; g, Commonwealth Serum Laboratories, Mel-
bourne, Australia (27); h, L.-H. Ping, University of North Carolina, Chapel
Hill, N.C. (this paper); i, R. Tedder, Middlesex Hospital, London, United
Kingdom.
" Maximum percent competition (at highest antibody concentration) against
polyclonal human antibody (JC) in a solid-phase radioimmunoassay employ-
ing HM175/18f antigen (34).
c Percent neutralization of HM175/18f virus achieved at working concen-
tration; titer is the loglo dilution of ascitic fluid or hybridoma culture
supernatant fluid resulting in 50% neutralization of HAV (HM175/18f or
HM175/p16) (34).
activity is a useful approach to characterizing monoclonal
antibodies to HAV. The results of these solid-phase radio-
immunoassays allowed us to categorize the antibodies into
the following five groups: group A, which almost completely
blocks the binding of K34C8 but does not reduce (and often
enhances) the binding of B5B3; group B, which has signifi-
cantly greater blocking activity against K34C8 than B5B3;
group C, which has strong and roughly equivalent blocking
activity against both K34C8 and B5B3; group D, which has
greater blocking activity against B5B3 than K34C8; and
group E, which includes only B5B3 and which has no
appreciable activity in blocking the binding of K34C8 (Fig.
2).
All but two antibodies (1.134 and LSH-14H) had substan-
tial neutralization activity against HM175/18f virus (>85%
reduction in infectious-virus titer) (Table 1). The two mono-
clonal antibody preparations with low neutralizing activity
(<50% neutralization), one of which was IgM(K) and the
other of which was IgG2A, were excluded from further
analysis.
Isolation of neutralization escape mutants. We have shown
previously that HM175 virus mutants with His or Ala
substitutions at Asp 3-070 resist neutralization by many
murine monoclonal antibodies (see mutants S30 and 43c in
Fig. 3) (31). Additionally, an escape mutant having a Leu
substitution at Ser 1-102 (mutant S32) demonstrated partial
resistance to several antibodies. As mutations at either of
these residues confer resistance to several antibodies (2D2,
B5B3, and 3E1), these data suggested that residues 3-070 and
1-102 both contribute to a single, dominant neutralization
site on the capsid surface (31). To test this hypothesis, we
determined whether multiple, independently selected mu-
tants capable of escaping neutralization by the monoclonal
antibody 2D2 would demonstrate mutations in both VP3 and
vP1.
The isolation of escape mutants resistant to 2D2 required
between three and six neutralization-amplification cycles, as
indicated in Table 2. Mutant viruses isolated from each of six
independent neutralization-amplification culture series failed
to bind 2D2 in an epitope-specific radioimmunofocus assay
(data not shown), but each was detected with radiolabelled
polyclonal human antibody. Two mutants were clonally
isolated from each of the six culture series (A through F).
Both clones from five of the six culture series had identical
mutations within the nucleotide sequence (and were thus
considered to be sibling clones), while the two mutants from
the remaining culture series (series B) each had unique
mutations. Thus, we isolated a total of seven independent
mutants that were resistant to 2D2. Each of these seven
mutants had closely spaced mutations within VP3 (3-070 or
3-074) (Table 2). Four mutants had an Asn substitution at
Asp 3-070, while two had a Tyr substitution at the same
residue and one had an Arg substitution at Gln 3-074. As we
have confirmed previously the involvement of residue 3-070
in the dominant antigenic site of HAV, we carried out only
limited sequencing of these VP3 mutants (Fig. 4).
We selected three other antibodies (AD2, AE8, and
H7C27) for the generation of additional escape mutants
because of evidence that these antibodies are directed
against epitopes that are distinct from that bound by 2D2.
Two of these antibodies have monoclonal antibody compe-
tition profiles in solid-phase radioimmunoassays that are
substantially different from that of 2D2 (AD2 and AE8 are in
group D, while 2D2 is in group B) (Fig. 2). The competition
profile of the third antibody, H7C27 (group C), is relatively
unique in that it has approximately equal blocking activity
against K34C8 and B5B3 but is unable to block the binding of
either more than about 70%. In addition, while resistance to
AD2 was conferred by a His substitution at Asp 3-070
(mutant S30), AE8 and H7C27 were able to neutralize
previously isolated 3-070 and 1-102 mutants (Fig. 3).
For both AD2 and AE8, we selected independent mutants
from three parallel neutralization-amplification culture se-
ries. These escape mutants generally required a higher
number of neutralization-amplification cycles for isolation
than escape mutants selected against 2D2, as resistant virus
was identified in only one of six culture series after four
cycles (series AE8-A), compared with five of six culture
series carried out in the presence of 2D2 (Table 2). While the
neutralization titer of the AD2 ascitic fluid (50% neutraliza-
tion endpoint between i0' and 10-4) was significantly lower
than that of 2D2 (between 10' and 10-6), this was not the
case with AE8 (also between 10' and 10-6). Thus, the
greater number of neutralization-amplification cycles re-
quired with AE8 and AD2 could be only partially related to
the lower level of neutralizing activity of these antibodies. In
addition to their lack of neutralization (c 10%) with the
cognate antibody, the AD2 and AE8 mutants failed to bind
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FIG. 2. Results of solid-phase radioimmunoassays examining the ability of monoclonal antibodies (labelled according to the first three or
four characters of each complete antibody designation shown in Table 1) to compete with radiolabelled antibodies K34C8 (solid columns) or
B5B3 (stippled columns) for binding to immobilized viral antigen. Monoclonal antibodies were characterized as belonging to one of five
different monoclonal antibody competition profile groups (A through E), as shown at the top of the figure. K34C8 and B5B3 antibodies utilized
as labelled reagents are boxed at the bottom of the figure.
this antibody in epitope-specific radioimmunofocus assays
(data not shown).
Two mutant viruses were clonally isolated from each
neutralization-amplification culture series. Both clonal vari-
ants isolated from each of the three culture series selected
for AE8 resistance had a Glu substitution at Val 1-171 (Table
2). The same substitution was also present in both clonal
isolates from one culture series selected for AD2 resistance
(series AD2-A), while an Asp substitution at Ala 1-176 was
found in both clonal isolates from each of the other two AD2
neutralization-amplification culture series (Table 2). As mu-
tations at 1-171 and 1-176 of HAV have not been associated
previously with neutralization escape, we determined the
complete P1 sequence of two representative mutants, llC
(Glu 1-171 selected against AE8) and 20D (Asp 1-176 se-
lected against AD2) (Fig. 4). In both cases, no other nonsi-
lent mutations from the HM175/18f parent nucleotide se-
quence were identified within the P1 region. These results
thus indicate that AD2 and AE8 recognize closely spaced
epitopes involving residues 171 and 176 of VP1.
We also selected mutants against antibody H7C27 in three
separate neutralization-amplification culture series. In each
case, escape mutants which failed to bind H7C27 in an
epitope-specific radioimmunofocus assay were present after
four cycles of neutralization-amplification (Table 2). Alto-
gether, five escape mutants were clonally isolated from the
three culture series and amplified for further analysis. We
found that each of these escape mutants had undergone
mutation within the Lys 1-221 codon (Table 2). One clonal
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FIG. 3. Cross-resistance of neutralization escape mutants to a panel of 22 neutralizing murine monoclonal antibodies. Eleven mutants
(listed to the right) representing unique amino acid substitutions within the capsid proteins (listed to the left) were characterized as resistant
(<30% neutralization) (solid boxes), partially resistant (30 to 60% neutralization) (hatched boxes), or sensitive (>60% neutralization) (stippled
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TABLE 2. Neutralization escape mutants derived from the HM175 strain of HAV6
Basechange ~~~~~~~~Substitution at:Antibody Mutant Series' Cyclec Base changeat position Asp 3-070 Gln 3-074 Ser 1-102 Val 1-171 Ala 1-176 Lys 1-221
K24F2 S30 A 3 1677 His
B5B3 S32 A 3 2512 Leu
43c 1678d Ala
30M 1677 Asn
27A A 6 1677 Asn
18A B 3 1677 Asn
3A B 4 1677 Tyr
2D2 7A C 4 1690 Arg
22A D 3 1677 Asn
28A E 3 1677 Tyr
34B F 3 1677 Asn
4C A 6 2719 Glu
AD2 16C B 6 2734 Asp
20D C 6 2734 Asp
40A A 4 2719 Glu
AE8 1iC B 6 2719 Glu
47M2 C 6 2719 Glu
15C A 4 2868 Glu
H7C27 20B B 4 2869 Met
33M C 4 2870 Asn
24B C 4 2870 Asn
a For completeness, two previously isolated mutants (S30 and S32) (31) and two spontaneous RR/CPE+ mutants (43c and 30M) (25) are included.
h Culture-selection series from which the mutant was isolated.
c Neutralization-amplification cycle at which the mutant was identified (see Materials and Methods).
d Also at positions 2797 and 3033.
to a base change at position 2868 (HM175 wild-type number-
ing), while two mutants from culture series B had a Met
1-221 substitution due to a base change at position 2869. On
the other hand, while both mutants (33M and 24B) isolated
from culture series C had Asn 1-221 substitutions, these
were due to different base changes at the third codon
position, 2870 (Table 2). Thus, four unique H7C27-resistant
mutants were isolated, each with amino acid replacements at
residue 1-221. As mutations at this residue have not been
associated previously with neutralization escape, we deter-
mined the complete P1 nucleotide sequence of mutant 33M
(Asn 1-221). We found no other nonsilent mutation from the
nucleotide sequence of the HM175/18f parent (Fig. 4).
Cross-resistance of escape mutants to other monoclonal
antibodies. We characterized the neutralization resistance
phenotype of escape mutants by testing each for resistance
to each of the 22 monoclonal antibodies which we found to
have significant neutralizing activity against the parent
HM175/18f virus (Table 1). For these studies, we included
mutant viruses with unique amino acid substitutions, select-
ing only one representative mutant when multiple mutants
with the same amino acid replacement had been isolated.
These results, in addition to neutralization results obtained
with three previously isolated mutants, S32, S30 and 43c, are
summarized in Fig. 3 (31). Neutralization resistance was
determined in radioimmunofocus reduction assays with con-
centrations of antibody which were capable of effectively
neutralizing an HM175/18f virus inoculum in parallel assays
(see Materials and Methods).
Mutants with amino acid substitutions at Asp 3-070 dem-
onstrated partial or complete neutralization resistance






























FIG. 4. Genomic regions sequenced within individual neutraliza-
tion escape mutants (listed at the left). The map of the P1 region of
the HM175 virus genome is shown at the top, with the location of
bases encoding each capsid protein indicated. Horizontal lines
indicate regions for which the nucleotide sequence was determined.
The complete P1 sequence of mutants S30, S32, 43c, 20D, l1C, and
33M has been determined. 0, nonsilent mutations within the nudle-
otide sequence; Ol, nonsilent mutations (from the wild-type virus)
present in the parent HM175/18f virus from which all mutants other
than S30, S32, and 43c were derived. Silent mutations are not
shown. The location of cDNA segments amplified by PCR for
sequence determination is shown at the bottom, with labels referring
to the primer sets described in Materials and Methods. Only one
virus for which two virus clones with identical mutations were
recovered from the same culture series is shown.
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mutant S32 (Leu 1-102, selected against B5B3) was sensitive
to neutralization by K24F2 according to the stringent criteria
for neutralization resistance employed in this study (<30%
neutralization for resistance and 30 to 60% neutralization for
partial resistance), we have previously shown in replicate
experiments that S32 is less susceptible to neutralization by
this antibody than is its parent, HM175/p16 virus (31). The
broadest resistance was observed with mutants which had
either His or Ala replacements at residue 3-070 (previously
isolated mutants S30 and 43c), while mutant 7A, which has
an Arg substitution at Gln 3-074, had a considerably nar-
rower resistance profile (Fig. 3). These results indicate that
residues Asp 3-070 and Gln 3-074 contribute to an important
neutralizing antigenic domain which is dominant in the
murine antibody response.
Mutants 20D and liC, which were selected against anti-
bodies AD2 and AE8, respectively, were also resistant to
H80C25, 7E7, and H29C26 (partial resistance only) (Fig. 3).
As resistance to AD2 and H80C25 was also conferred by a
His substitution at Asp 3-070, these results indicate that Val
1-171 and Ala 1-176 (sites of mutations in llC and 20D)
contribute to this same immunodominant antigenic site. This
was further confirmed by the resistance pattern of mutant
S32. This mutant has a Leu replacement at Ser 1-102 (31) and
was partially resistant to antibodies 2D2, 3E1, and H80C25,
as well as B5B3, against which it was originally selected (34).
Thus, the dominant antigenic site of HAV includes contri-
butions from Asp 3-070, Gln 3-074, Ser 1-102, Val 1-171, and
Ala 1-176. A total of 20 of 22 murine neutralizing antibodies
may be related to this site by resistance due to mutations at
one or more of these residues (Fig. 3). This site is complex,
however, and contains multiple epitopes, as resistance to
most individual antibodies was mediated by mutations
within only one or two putative protein loops on the surface
of the capsid. Antibody H80C25 represents an exception to
this statement, however, as partial or complete resistance
was mediated by substitutions within the three putative
protein loops containing residue 3-070, 1-102, or 1-171 and
1-176.
All three escape mutants with unique substitutions at Lys
1-221 were resistant only to antibody H7C27, the antibody
against which they had been selected (Fig. 3). Conversely,
this antibody effectively neutralized all of the remaining
escape mutants. Thus, the available data suggest that the
antigenic site identified by mutations at Lys 1-221 may be
functionally distinct from the immunodominant site de-
scribed above. Similarly, antibody 4E7 neutralized each of
the escape mutants, including those with mutations at Lys
1-221 (Fig. 3). Thus, the antigenic site against which 4E7 is
directed remains undefined and may possibly represent yet a
third, functionally independent site.
DISCUSSION
Although the structures of the capsids of representative
members of each of the four other picornaviral genera have
been determined by X-ray crystallography (1, 15, 26, 32),
this has not yet been accomplished for HAV because of the
difficulties inherent in producing sufficient quantities of virus
for such studies. However, it is likely that the structure of
HAV resembles that determined for other picomaviruses in
terms of the general orientation of the individual proteins
within the capsid and the presence of an 8-stranded, anti-
parallel ,-barrel structural motif with flanking loop regions
which is shared by the capsid proteins of other picornavi-
ruses. Moreover, the approximate locations of the 1-strands
and intervening loop sequences of HAV may be inferred by
sophisticated methods of examination of alignments of the
amino acid sequences of HAV with those of other picorna-
viruses (29).
The data we report in this paper generally support the
existence of two independent antigenic sites on the HAV
capsid. One of these sites can be considered immunodomi-
nant in the mouse, as most murine neutralizing monoclonal
antibodies are directed against epitopes within it. This im-
munodominant site is defined by mutations at residues 3-070
and 3-074, as well as at residues 1-102, 1-171, and 1-176.
These latter residues align approximately with the B-C and
E-F loops of VP1 of Mengo virus (MV), a murine cardiovi-
rus, while residues 3-070 and 3-074 of HAV align with the
VP3 "knob" of MV (29, 26). Although there is little relat-
edness evident in the amino acid sequences of the capsid
proteins of HAV and MV (35), these two picornaviruses are
similar in terms of the probable location of the primary
polyprotein cleavage event (3), the probable presence of a
leader (L) peptide (8), and (perhaps most significant) con-
served RNA structural motifs within the 5' nontranslated
region of the genome (7). In contrast, the enteroviruses
(among which HAV was classified previously) and the
rhinoviruses differ from the cardioviruses and the hepatovi-
ruses in each of these three respects. Consistent with this
structural alignment, the predicted VP3 knob figures prom-
inently in the antigenic structure of HAV, as it does in MV
(6). However, functional relatedness and close structural
proximity of the VP1 B-C and E-F loops to the VP3 knob in
HAV are suggested by the pattern of cross-resistance found
with escape mutants (Fig. 3). This was most evident with
antibodies H80C25 and AD2 in particular.
Residue 1-221 of HAV aligns with the base of the "FMDV
loop" (G-H loop) of VP1 in MV (29). This loop represents an
important antigenic site in the aphthoviruses and is known to
function as a continuous antigenic determinant in foot-and-
mouth disease virus (FMDV) (1, 5). In HAV, the data
suggest that this loop is antigenic but potentially independent
of the dominant antigenic site described above. Mutations at
residue 1-221 were selected only by antibody H7C27, and
this antibody neutralized all other escape mutants. In previ-
ous collaborative work with Cox and Feinstone, however,
we showed that a genetically engineered HM175 variant
having a Ser-to-Glu substitution at residue 1-114 was par-
tially resistant to H7C27 but well neutralized by other
antibodies (11). Thus, the resistance phenotype of this
engineered mutant was similar to that of the 1-221 mutants
shown in Fig. 4, suggesting that residues 1-114 and 1-221
may contribute to the same site. However, residue 1-114 of
HAV aligns with the base of the B-C loop of VP1 in MV,
opposite the residue aligning with 1-102 of HAV. It is thus
tempting to speculate that this site is in fact in very close
proximity and perhaps part of the immunodominant anti-
genic site of HAV, but further study will be required to
confirm or refute this hypothesis.
Antibodies K34C8 and B5B3 both recognize epitopes
within the dominant antigenic site. Although no one mutant
was resistant to both K34C8 and B5B3, resistance to several
other antibodies (2D2, 3E1, and H80C25) could be conferred
by mutations at both residues (3-070 and 1-102) implicated in
K34C8 and B5B3 resistance, respectively (Fig. 3). These
results are consistent with the fact that the two antibodies
bind semiindependently to the capsid surface. They do not
compete with each other in solid-phase binding assays but
rather demonstrate a binding enhancement effect, suggesting
that they recognize closely spaced epitopes (Fig. 2) (31, 34).
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Thus, the immunodominant antigenic site must span an area
with a diameter at least twice that of a typical Fab fragment
footprint.
In crystallographic studies of an antigen-antibody com-
plex, the footprint of an Fab antibody fragment binding to
lysozyme has been shown to cover approximately 750 A2 of
the solvent-accessible surface of the enzyme (2). The com-
plementarity-determining regions of the antibody were found
to be in close contact with 16 amino acid residues of the
antigen. Similar X-ray crystallographic analysis of com-
plexes of Fab fragments with influenza virus neuraminidase
tetramers demonstrated a comparable number of amino acid
residues contacted in the antigen (10). It thus seems reason-
able to assume that antibodies which neutralize HAV closely
contact an approximately equal number of residues within
the solvent-accessible surface of the capsid proteins. How-
ever, when we examined multiple, independent escape mu-
tants selected for neutralization resistance to individual
monoclonal antibodies, we found mutations at only one or,
at most, two amino acid positions (Table 2). For example,
six of seven mutants selected against 2D2 had mutations at
residue 3-070, while all four independently selected H7C27
mutants had amino acid substitutions (due to different nu-
cleotide base substitutions) at residue 1-221. The very re-
stricted number of residues we identified as sites of mutation
could reflect very stringent structural constraints imposed by
the need to retain biological activity of the capsid. However,
these data are also compatible with the existence of key
amino acid residues which play a critical role in determining
the avidity of particular neutralizing antibodies for the virus
capsid.
In interpreting the results of these experiments, we have
considered it likely that the sites of mutations which we have
identified are located within the region of the capsid which is
actually contacted by neutralizing antibody. This is a rea-
sonable assumption, given that this has been shown to be the
case for almost all mutations responsible for neutralization
escape in those picornaviruses for which the three-dimen-
sional structure has been determined (1, 28, 32). However, a
clear-cut exception to this paradigm was recently demon-
strated by Parry et al. (30), who found that neutralization
resistance could be conferred by amino acid substitutions
occurring outside a neutralization epitope on the surface of
FMDV (serotype 0). Thus, the potential for functionally
significant perturbations of the capsid structure occurring at
some distance from the site of a mutation must be consid-
ered, although such a mechanism of neutralization escape
cannot be documented in the absence of definitive crystal-
lographic studies.
Although the work described in this report was carried out
entirely with murine monoclonal antibodies, we have re-
cently found that human monoclonal antibodies recognize
similar epitopes on the capsid surface. Although these stud-
ies remain in progress, partial or complete neutralization
resistance to two of three human monoclonal antibodies is
conferred by amino acid substitutions at Asp 3-070 or Ser
1-102 (13a). Thus, there is at present little evidence to
suggest significant differences in the antibody repertoires
developed against HAV in mice and in humans. This con-
trasts with a previous report that human and murine anti-
bodies differ with respect to their binding sites on the
poliovirus capsid (36) and may reflect a relatively limited
number of potentially antigenic sites present on the HAV
capsid.
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ADDENDUM IN PROOF
Y. Moritsugu and coworkers have isolated neutralization
escape variants from the KRM003 strain of HAV (Moritsugu
et al., unpublished data). With several exceptions, the loca-
tions of escape mutations in the capsid proteins of the
KRM003 mutants are very similar to those which we iden-
tified in our HM175 escape mutants. However, these work-
ers were not able to establish a pattern of cross-resistance
between mutants with substitutions in the vicinity of 3-070
and those with substitutions at 1-100 or 1-174 with the
monoclonal antibodies available to them. The KRM003 and
HM175 viruses, although both of human origin, are diver-
gent genetically and represent distinctly different genotypes
of human HAV (17).
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